Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL415622 | 0.86 | CALM1 (0.50) | HTR2BCALM1POLBALDH1A1TDP1 | |
| SCHEMBL752939 | 0.83 | KCNH2 (0.47) | ALDH1A1MAPK1MAOBLMNAHPGD | |
| SCHEMBL13098271 | 0.80 | NOS3 (0.50) | ALDH1A1L3MBTL1ALOX15HPGD | |
| SCHEMBL27615865 | 0.80 | SMN1; SMN2 (0.49) | RAB9ASMN1; SMN2HTT | |
| SCHEMBL3923373 | 0.77 | BCL2 (0.44) | HTR2BCALM1ALDH1A1TDP1RAB9A | |
| SCHEMBL20348519 | 0.77 | LOXL2 (0.43) | HTR2BCALM1ALDH1A1TDP1RAB9A | |
| SCHEMBL3913251 | 0.77 | ALDH1A1 (0.52) | HTR2BCALM1POLBALDH1A1TDP1 | |
| SCHEMBL23020320 | 0.76 | MIF (0.52) | HTR2BCALM1ALDH1A1TDP1RAB9A | |
| SCHEMBL24076907 | 0.74 | CYP2A6 (0.31) | — | |
| SCHEMBL27585477 | 0.74 | HTR2B (0.40) | HTR2BCALM1POLBALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773065-B2 | Heterocyclic g-protein-coupled receptor 52 (GPR52) agonists | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220112164-A1 | HETEROCYCLIC G-PROTEIN-COUPLED RECEPTOR 52 (GPR52) AGONISTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2022-04-14 | — | — | US | disclosed |
| US-9040529-B2 | 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2015-05-26 | — | — | US | disclosed |
| US-20120258968-A1 | 4-PHENYLAMINO-PYRIMIDINE DERIVATIVES HAVING PROTEIN KINASE INHIBITOR ACTIVITY | VIROSTATICS S.R.L. (IT) | 2012-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112164-A1 | HETEROCYCLIC G-PROTEIN-COUPLED RECEPTOR 52 (GPR52) AGONISTS | GPR52, GPR68, GPR65 | HTR2B 131/4885CALM1 2096/4885POLB 4818/4885 |
| US-20120258968-A1 | 4-PHENYLAMINO-PYRIMIDINE DERIVATIVES HAVING PROTEIN KINASE INHIBITOR ACTIVITY | CDK9, CDK19, CDKL3 | HTR2B 2879/4885CALM1 1348/4885POLB 1020/4885 |
| US-11773065-B2 | Heterocyclic g-protein-coupled receptor 52 (GPR52) agonists | GPR52, GPR68, GPR65 | HTR2B 131/4885CALM1 2096/4885POLB 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.